Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention Therapy, Tianjin, China.
Ann Surg Oncol. 2019 Sep;26(9):2890-2898. doi: 10.1245/s10434-019-07393-w. Epub 2019 Jun 10.
Effective tools evaluating the prognosis for patients with esophageal cancer undergoing surgery is lacking. The current study aimed to develop a nomogram to predict overall survival (OS) and provide evidence for adjuvant therapy for patients with esophageal carcinoma after esophagectomy.
The study retrospectively reviewed patients with pathologic T1N +/T2-4aN0-3, M0 thoracic esophageal squamous cell carcinoma after radical esophagectomy, with or without adjuvant therapy, in one institution as the training cohort (n = 2281). A nomogram was established using Cox proportional hazard regression to identify prognostic factors for OS, which were validated in an independent validation cohort (n = 1437). Area under curve (AUC) values of receiver operating characteristic curves were calculated to evaluate prognostic efficacy.
In the training cohort, the median OS was 50.46 months, and the 5-year OS rate was 47.08%. Adjuvant therapy, sex, tumor location, grade, lymphovascular invasion, removed lymph nodes, and T and N categories were identified as predictive factors for OS. The nomogram showed favorable prognostic efficacy in the training and validation cohorts (5-year OS AUC: 0.685 and 0.744, respectively), which was significantly higher than that of the American Joint Committee on Cancer (AJCC) staging system. The nomogram distinguished OS rates among six risk groups, whereas AJCC could not separate the OS of 2A and 1B, 3C and 3B, or 3A and 2B. Patients with a nomogram score of 72 to 227 were predicted to achieve a 5-year OS increase of 10% or more from adjuvant therapy.
The nomogram could effectively predict OS and aided decision making in adjuvant therapy for patients with thoracic esophageal squamous cell carcinoma after esophagectomy.
目前缺乏用于评估接受手术治疗的食管癌患者预后的有效工具。本研究旨在开发一种列线图来预测总体生存(OS),并为食管癌根治术后接受辅助治疗的患者提供依据。
本研究回顾性分析了一家机构中接受根治性食管切除术且接受或未接受辅助治疗的病理 T1N+/T2-4aN0-3、M0 胸段食管鳞癌患者的资料,作为训练队列(n=2281)。使用 Cox 比例风险回归建立列线图,以确定 OS 的预后因素,并在独立验证队列(n=1437)中进行验证。计算受试者工作特征曲线的曲线下面积(AUC)值来评估预测效能。
在训练队列中,中位 OS 为 50.46 个月,5 年 OS 率为 47.08%。辅助治疗、性别、肿瘤位置、分级、脉管侵犯、清扫淋巴结数目以及 T 和 N 分期被确定为 OS 的预测因素。列线图在训练和验证队列中均显示出良好的预后预测效能(5 年 OS AUC:分别为 0.685 和 0.744),明显高于美国癌症联合委员会(AJCC)分期系统。列线图可将 OS 率区分在 6 个风险组中,而 AJCC 分期系统不能区分 2A 期和 1B 期、3C 期和 3B 期或 3A 期和 2B 期。列线图评分在 72 至 227 分的患者被预测可从辅助治疗中获得 5 年 OS 提高 10%或以上。
列线图可有效预测 OS,并有助于辅助治疗决策,为食管癌根治术后患者提供依据。